Prestige Wealth Management Group LLC Boosts Stock Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 910.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,071 shares of the company’s stock after buying an additional 965 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Tempus AI were worth $36,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI in the third quarter worth about $30,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC purchased a new stake in Tempus AI in the 4th quarter worth approximately $67,000. IFP Advisors Inc bought a new position in Tempus AI in the 4th quarter valued at $76,000. Finally, US Bancorp DE purchased a new position in shares of Tempus AI during the 4th quarter valued at $80,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

TEM has been the subject of several research analyst reports. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Bank of America lifted their price target on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley upped their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, Piper Sandler lowered their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Price Performance

NASDAQ:TEM opened at $58.57 on Wednesday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company has a fifty day moving average of $57.42 and a 200 day moving average of $51.46.

Insider Activity

In related news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.00. Following the sale, the chief operating officer now owns 982,442 shares in the company, valued at $38,914,527.62. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the transaction, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,598,969 shares of company stock valued at $317,194,162.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.